Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Canagliflozin and mTOR: A Translational Map
2026-08-26
Canagliflozin hemihydrate is a focused SGLT2 probe for glucose metabolism research. New yeast-based evidence finds no TOR inhibition under the tested conditions, helping translational teams separate renal glucose reabsorption biology from mTOR pathway claims and design cleaner validation strategies.
-
Streptavidin-FITC for LNP Trafficking Assays
2026-08-25
Streptavidin-FITC can do more than reveal biotinylated targets: it can help distinguish cargo retention from nanoparticle trafficking in LNP studies. This guide translates recent mechanistic findings into practical assay-design, labeling, imaging, and interpretation decisions.
-
Streptozotocin Workflows for Diabetes Research
2026-08-25
Build more reproducible diabetes models with STZ by connecting β-cell injury, glucose confirmation, and neuropathy-focused readouts in one workflow. This guide distinguishes exploratory cell assays from animal induction studies and translates TBK1–microglia findings into practical experimental decisions.
-
Mitomycin C Workflows for Cancer Research
2026-08-24
Mitomycin C is an antitumor antibiotic that gives cancer researchers a controllable way to study DNA replication inhibition, proliferation arrest, and apoptosis sensitization. This workflow-led guide covers stock preparation, dose finding, TRAIL combination experiments, immune-assay extensions, and troubleshooting for reproducible results.
-
Type III Collagen Restricts Breast Cancer Progression
2026-08-24
The 2024 npj Breast Cancer study identifies type III collagen as a tumor-restrictive component of the breast cancer microenvironment rather than merely a structural matrix protein. By integrating fibroblast-derived matrices, patient tissue analysis, TCGA-BRCA bioinformatics, 3D culture, and mouse models, the authors show that increasing the type III-to-type I collagen balance may help restrain tumor growth and metastasis.
-
Mechanical Stress, Cytoskeleton, and Autophagy
2026-08-23
The reference study shows that compressive force-induced autophagy depends primarily on cytoskeletal microfilaments, while microtubules provide auxiliary support. Its combination of mechanical stimulation, cytoskeletal perturbation, fluorescence imaging, and western blotting offers a framework for distinguishing force sensing from downstream autophagic responses.
-
Losartan Workflows for AT1 and Vascular Research
2026-08-22
Losartan is a practical angiotensin II receptor antagonist for connecting AT1 signaling with vascular remodeling, blood-pressure phenotypes, and matrix biology. This workflow-oriented guide covers assay setup, formulation, vascular smooth muscle cell proliferation inhibition, and a carefully bounded extension into tumor mechanical microenvironment research.
-
Viral vIRD Control of RIPK3 and Inflammation
2026-08-22
Liu and colleagues identified vIRD, a cowpox virus and orthopoxvirus protein that recruits the SCF machinery to drive proteasomal degradation of RIPK3, thereby suppressing necroptosis. Viral engineering and mouse genetic experiments showed that vIRD is not simply an immune-evasion factor: its interaction with RIPK3 shapes viral replication, inflammation, mortality, and pathogen–host evolution.
-
FCCP as a Systems Probe of Mitochondrial Signaling
2026-08-21
FCCP is more than an oxidative phosphorylation uncoupler: it is a strategic perturbation tool for connecting mitochondrial energetics with HIF signaling, metabolic phenotypes, and organelle quality control. This article interprets FCCP through the emerging MARCH5–PEX3 pre-peroxisome axis and offers a translational framework for experimental design, controls, and responsible interpretation.
-
HD56 Prodrug Metabolism in Humanized Mice
2026-08-20
The reference study shows that humanized-liver mice can resolve species-dependent differences in the activation and disposition of the CES-sensitive prodrug HD56. Its strong in vivo–in vitro correlation, together with transporter, enzyme, microsomal, plasma, and pharmacokinetic experiments, provides a practical framework for improving preclinical translation of ester prodrugs.
-
Marein Reverses ABCG2-Mediated Mitoxantrone Resistance
2026-08-20
The reference study identifies marein, a flavonoid from Coreopsis tinctoria, as a competitive inhibitor of the ABCG2 drug efflux transporter. By increasing intracellular concentrations of ABCG2 substrates, including Mitoxantrone, marein restored drug sensitivity in resistant cancer-cell models and linked this activity to the conserved F439 residue of ABCG2.
-
Iptacopan (LNP023) Workflows for Complement Research
2026-08-19
Build more interpretable complement experiments with Iptacopan (LNP023), from alternative-pathway C3bBb inhibition to PNH hemolysis and animal-model studies. This guide combines practical assay design, quantitative controls, troubleshooting, and a risk-modeling insight from a major anticoagulation study.
-
SVA 3A and 2B Counter DDX23 Through Apoptosis
2026-08-19
The reference study defines a dual host–virus interaction in which DDX23 restricts Senecavirus A (SVA) by promoting 3A degradation through a caspase-2/caspase-6 pathway, while SVA 2B promotes DDX23 loss through a caspase-2/caspase-3 route. By combining DDX23 perturbation, pathway inhibitor experiments, and reverse genetics, the authors identify viral residues that regulate this antagonism and may guide future SVA antiviral or vaccine studies.
-
Urolithin A: Reliable Cell Assay Workflows
2026-08-18
This scenario-based guide explains how Urolithin A (SKU B7945) can be incorporated into reproducible cell viability, proliferation, and cytotoxicity workflows without confusing mitochondrial effects with cell loss. It covers solvent compatibility, protocol controls, interpretation of hepatic stellate cell data, and practical vendor-selection criteria.
-
Latrunculin B: Actin Assay Workflow and Troubleshooting
2026-08-18
Latrunculin B enables rapid, reversible actin filament assembly inhibition for time-resolved cytoskeletal experiments. Its transient activity also makes it a useful mechanistic control in endocytosis and viral-entry assays, where exposure conditions and serum effects must be interpreted carefully.